U. Griesenbach

发表

Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence.

D. Geddes, M. Evans, W. Colledge, 2001, The European respiratory journal.

Basic science: What will it deliver? Gene and stem cell therapy

E. Alton, U. Griesenbach, 2015 .

Identification and Functional Characterization of Cytoplasmic Determinants of Plasmid DNA Nuclear Import*

D. Geddes, M. Ward, M. Dunn, 2009, The Journal of Biological Chemistry.

Assessment of the nuclear pore dilating agent trans‐cyclohexane‐1,2‐diol in differentiated airway epithelium

R. Scheule, Seng H. Cheng, E. Alton, 2012, The journal of gene medicine.

TITLE Towards Gene Therapy for Cystic Fibrosis Using a Lentivirus Pseudotyped With Sendai Virus Envelopes

K. Mitomo, Y. Ueda, M. Hasegawa, 2015 .

Moving forward: cystic fibrosis gene therapy.

E. Alton, U. Griesenbach, 2013, Human molecular genetics.

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

D. Porteous, J. Davies, M. Hasegawa, 2012, American journal of respiratory and critical care medicine.

P95 Assessment of F/HN-pseudotyped Lentivirus as a Clinically Relevant Vector For Lung Gene Therapy

J. Davies, M. Hasegawa, D. Gill, 2012, Thorax.

Detection of CFTR transgene mRNA expression in respiratory epithelium isolated from the murine nasal cavity

D. Porteous, R. Scheule, Seng H. Cheng, 2010, The journal of gene medicine.

Quantification of periciliary fluid height in human airway biopsies is feasible, but not suitable as a biomarker.

P. Shah, A. Bush, J. Davies, 2011, American journal of respiratory cell and molecular biology.

Gene therapy progress and prospects: cystic fibrosis

E. Alton, D. Geddes, U. Griesenbach, 2002, Gene Therapy.

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins

L. Davies, S. Hyde, I. Pringle, 2018, Gene Therapy.

Critical appraisal of the mouse model of myocardial infarction

D. Geddes, Kaori Sato, Jie Zhu, 2004, Experimental physiology.

Effects of intramyocardial pVEGF165 delivery on regional myocardial blood flow: evidence for a spatial ‘delivery–efficacy’ mismatch

P. Radke, E. Alton, S. Ferrari, 2004, Gene Therapy.

Efficient gene transfer to airway epithelium using recombinant Sendai virus

D. Geddes, Y. Yonemitsu, Y. Nagai, 2000, Nature Biotechnology.

Intravenously administered oligonucleotides can be delivered to conducting airway epithelium via the bronchial circulation

D. Rogers, E. Alton, L. Huang, 2006, Gene Therapy.

The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways.

R. Scheule, Seng H. Cheng, P. Sinn, 2010, Biomaterials.

Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo

D. Geddes, R. Scheule, C. Plank, 2006, Gene Therapy.

Preparation for a fi rst-inman lentivirus trial in patients with cystic fi brosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016 .

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016, Thorax.

Comparison of DNA strand break induction in CHO cells measured by alkaline elution and by fluorometric analysis of DNA unwinding (FADU).

H. Rink, U. Griesenbach, C. Baumstark‐Khan, 1992, Free radical research communications.

Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo

N. Caplen, R. Scheule, Seng H. Cheng, 2006, Respiratory research.

Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer.

M. J. Roberts, R. Scheule, Seng H. Cheng, 2011, Biomaterials.

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung

D. Porteous, D. Shaw, R. Scheule, 2011, Gene Therapy.

The pathogenic consequences of a single mutated CFTR gene

D. Geddes, U. Griesenbach, E. Alton, 1999, Thorax.

Transfection efficiency and toxicity following delivery of naked plasmid DNA and cationic lipid-DNA complexes to ovine lung segments.

D. Porteous, Seng H. Cheng, S. Hyde, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Anti-inflammatory gene therapy directed at the airway epithelium

D. Geddes, Leaf Huang, E. Alton, 2000, Gene Therapy.

Progress and Prospects: Gene Therapy Clinical Trials (Part 2)

U. Griesenbach, 2007, Gene Therapy.

The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro

E. Alton, F. Sorgi, L. Huang, 1998, Gene Therapy.

The role of doxorubicin in non-viral gene transfer in the lung.

R. Scheule, Seng H. Cheng, E. Alton, 2009, Biomaterials.

Expression and maturation of Sendai virus vector-derived CFTR protein: functional and biochemical evidence using a GFP-CFTR fusion protein

M. Hasegawa, E. Alton, A. Iida, 2007, Gene Therapy.

Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction

E. Alton, U. Griesenbach, 2015, F1000prime reports.

Gene therapy for asthma: inspired research or unnecessary effort?

D. Geddes, E. Alton, U. Griesenbach, 1999, Gene Therapy.

Cystic fibrosis modifier genes.

J. Davies, U. Griesenbach, E. Alton, 2005, Journal of the Royal Society of Medicine.

Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa.

L. Tsui, D. Radzioch, D. Eidelman, 1998, American journal of respiratory and critical care medicine.

Sendai virus-mediated CFTR gene transfer to the airway epithelium

A. M. Wright, D. Geddes, B. Wainwright, 2007, Gene Therapy.

Gene Therapy Progress and Prospects: Cystic fibrosis

D. Geddes, E. Alton, S. Ferrari, 2002, Gene Therapy.

S127 Gene therapy for alpha-1-antitrypsin deficiency using a pseudotyped lentivirus vector

M. Hasegawa, I. Pringle, D. Gill, 2015 .

Immunological hurdles to lung gene therapy

D. Geddes, E. Alton, S. Ferrari, 2003, Clinical and experimental immunology.

CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression

David N Sheppard, Uta Griesenbach, David J Porteous, 2008, Nature Biotechnology.

Progress in Respiratory Gene Therapy

J. Davies, S. Hyde, D. Gill, 2022, Human gene therapy.

Cystic fibrosis gene therapy: a mutation-independent treatment

J. Davies, E. Alton, U. Griesenbach, 2016, Current opinion in pulmonary medicine.

Gene therapy for cystic fibrosis: recent progress and current aims

E. Alton, U. Griesenbach, Robyn V. Bell, 2016 .

Preparation for a ﬁ rst-in-man lentivirus trial in patients with cystic ﬁ brosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016 .

A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial.

D. Porteous, J. Davies, S. Hyde, 2015, American journal of respiratory and critical care medicine.

Clinical Development of an Optimal F/HN Pseudotyped SIV Vector for Cystic Fibrosis Lung Gene Therapy

A. Inness, J. Davies, M. Hasegawa, 2014 .

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung

D. Porteous, R. Scheule, J. Davies, 2013, Gene Therapy.

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.

D. Porteous, D. Shaw, R. Scheule, 2013, Biomaterials.

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis

D. Porteous, G. Murray, Seng H. Cheng, 2013, Thorax.

An immunocytochemical assay to detect human CFTR expression following gene transfer.

A. Nairn, D. Porteous, R. Gray, 2009, Molecular and cellular probes.

Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression

S. Hyde, D. Gill, E. Alton, 2022, Molecular therapy. Methods & clinical development.

Validation of recombinant Sendai virus in a non-natural host model

T. Shu, M. Hasegawa, G. Mclachlan, 2011, Gene Therapy.

Low-frequency ultrasound increases non-viral gene transfer to the mouse lung.

D. Geddes, R. Scheule, Seng H. Cheng, 2010, Acta biochimica et biophysica Sinica.

Cytoplasmic deposition of NFκB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation

E. Alton, R. Cassady, D. Geddes, 2002, Gene Therapy.

Comparison between intratracheal and intravenous administration of liposome–DNA complexes for cystic fibrosis lung gene therapy

L. Tsui, C. Ackerley, A. Tanswell, 1998, Gene Therapy.

Oral contraceptives do not appear to affect cystic fibrosis disease severity

P. Cullinan, E. Alton, D. Bilton, 2012, European Respiratory Journal.

Validation of nasal potential difference measurements in gut-corrected CF knockout mice.

Charanjit Singh, E. Alton, R. Farley, 2008, American journal of respiratory cell and molecular biology.

CFTR gene transfer to human cystic fibrosis pancreatic duct cells using a Sendai virus vector

A. Mehta, P. Hegyi, Z. Rakonczay, 2008 .

Update on Preclinical and Clinical Gene Therapy for the Treatment of Cystic Fibrosis

E. Alton, U. Griesenbach, 2015 .

Optimizing aerosol gene delivery and expression in the ovine lung.

D. Porteous, R. Scheule, Seng H. Cheng, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Nasal abnormalities in cystic fibrosis mice independent of infection and inflammation.

A. Bush, B. Wainwright, J. Davies, 2008, American journal of respiratory cell and molecular biology.

Advances in cystic fibrosis gene therapy

D. Geddes, E. Alton, U. Griesenbach, 2004, Current opinion in pulmonary medicine.

Milking gene therapy

D. Geddes, E. Alton, U. Griesenbach, 1998, Nature Medicine.

Self-reactive CFTR T cells in humans: implications for gene therapy.

D. Porteous, James M. Wilson, J. Davies, 2013, Human gene therapy. Clinical development.

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

Steve Cunningham, Joseph Jacob, Sarah Sheard, 2015 .

Cystic Fibrosis Gene Therapy – Not Low-hanging Fruit

E. Alton, U. Griesenbach, 2016 .

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016, Thorax.

Special focus issue on the annual meeting of the British Society for Gene and Cell Therapy.

S. Nicklin, U. Griesenbach, A. Baker, 2015, Human gene therapy.

Gene therapy for cystic fibrosis: an example for lung gene therapy

E. Alton, D. Geddes, U. Griesenbach, 2004, Gene therapy.

In vivo imaging of gene transfer to the respiratory tract.

D. Geddes, R. Scheule, Seng H. Cheng, 2008, Biomaterials.

Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung

D. Geddes, D. Altmann, R. Boyton, 2006, Gene Therapy.

Genetic medicines for CF: Hype versus reality

J. Davies, S. Hyde, D. Gill, 2016, Pediatric pulmonology.

Cystic Fibrosis Gene Therapy in the UK and Elsewhere

E. Alton, U. Griesenbach, K. Pytel, 2015, Human gene therapy.

Expert opinion in biological therapy: update on developments in lung gene transfer

E. Alton, U. Griesenbach, 2013, Expert opinion on biological therapy.

Viral vectors for cystic fibrosis gene therapy: What does the future hold?

M. Hasegawa, E. Alton, U. Griesenbach, 2010 .

Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy.

E. Alton, U. Griesenbach, 2009, Advanced drug delivery reviews.

Use of ultrasound to enhance nonviral lung gene transfer in vivo

D. Geddes, R. Scheule, E. Alton, 2007, Gene Therapy.

Progress and prospects: gene therapy clinical trials (part 1) (vol 14, pg 1439, 2007)

R. Ali, J. Bainbridge, T. Flotte, 2007 .

Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy.

A. Boyd, U. Griesenbach, A. Boyd, 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis

J. Davies, E. Alton, E. Hollox, 2005, Journal of Negative Results in BioMedicine.

Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.

Raymond Farley, Uta Griesenbach, Makoto Inoue, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Pretreatment with cationic lipid-mediated transfer of the Na+K+-ATPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedema

E. Alton, S. Cheng, Y. Berthiaume, 2000, Gene Therapy.

Lung disease in mice with cystic fibrosis.

L. Tsui, C. McKerlie, C. Ackerley, 1997, The Journal of clinical investigation.

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.

J. Lueck, B. Kerem, N. Allaire, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli

D. Geddes, R. Scheule, E. Alton, 2008, Gene Therapy.

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation

D. Hansell, D. Porteous, D. Ashby, 2013, Thorax.

Emerging significance of plasmid DNA nuclear import in gene therapy.

D. Dean, E. Alton, U. Griesenbach, 2003, Advanced drug delivery reviews.

Cystic fibrosis gene therapy: successes, failures and hopes for the future

E. Alton, U. Griesenbach, 2009, Expert review of respiratory medicine.

Cystic fibrosis: Ferreting with fibroblasts for cystic fibrosis

E. Alton, U. Griesenbach, 2009, Gene Therapy.

Gene therapy for respiratory diseases; progress and a changing context.

J. Davies, S. Hyde, D. Gill, 2020, Human gene therapy.

Magnetic nanoparticles as gene delivery agents: enhanced transfection in the presence of oscillating magnet arrays

A. Keramane, C. Batich, J. Dobson, 2008, Nanotechnology.

Deficient retinoid-driven angiogenesis may contribute to failure of adult human lung regeneration in emphysema

M. Hind, M. Griffiths, C. Dean, 2017, Thorax.

Progress in gene and cell therapy for cystic fibrosis lung disease.

E. Alton, U. Griesenbach, 2012, Current pharmaceutical design.

Recent progress in gene therapy for cystic fibrosis.

E. Alton, U. Griesenbach, 2001, Current opinion in molecular therapeutics.

Sendai virus for gene therapy and vaccination.

M. Hasegawa, E. Alton, U. Griesenbach, 2005, Current opinion in molecular therapeutics.

A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo

D. Geddes, T. Shu, M. Hasegawa, 2004, Gene Therapy.

Assessment of CFTR function after gene transfer in vitro and in vivo.

S. Hyde, S. Sumner-Jones, D. Gill, 2008, Methods in molecular biology.

Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis

E. Alton, U. Griesenbach, 2011, BioDrugs.

Cystic fibrosis in the 21st century

A. Bush, J. Davies, E. Alton, 2005 .

The nasal epithelium as a factory for systemic protein delivery.

D. Geddes, Y. Nagai, E. Schmitt, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Vascular oligonucleotide transfer facilitated by a polymer-coated stent.

D. Geddes, P. Radke, E. Alton, 2005, Human gene therapy.

T4 Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis

R. Scheule, S. Hyde, D. Gill, 2011, Thorax.

Modifier genes in cystic fibrosis

J. Davies, E. Alton, U. Griesenbach, 2004, Pediatric pulmonology.

Update on gene therapy for cystic fibrosis.

D. Geddes, E. Alton, U. Griesenbach, 2003, Current opinion in molecular therapeutics.

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator ( CFTR) gene therapy in patients with cystic fibrosis

A. Nicholson, D. Hansell, A. Maclean, 2016 .

Limitations of the murine nose in the development of nonviral airway gene transfer.

D. Porteous, Charanjit Singh, R. Scheule, 2010, American journal of respiratory cell and molecular biology.

Molecular Therapies for Cystic Fibrosis

J. Davies, E. Alton, G. Davies, 2019, Kendig's Disorders of the Respiratory Tract in Children.

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins

L. Davies, S. Hyde, I. Pringle, 2018, Gene Therapy.

534. Preparation for a First-in-Man Lentivirus Trial in Cystic Fibrosis Patients

J. Davies, M. Hasegawa, L. Davies, 2016 .

RESPIRATORIO Lung Disease in Mice with Cystic Fibrosis

L. Tsui, C. McKerlie, C. Ackerley, 1997 .

Title Lung disease in mice with cystic fibrosis

A. Tanswell, M. Buchwald, L. Huan, 1997 .

Cystic Fibrosis Gene Therapy

D. Geddes, E. Alton, U. Griesenbach, 1999 .

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

A. Nicholson, D. Hansell, A. Maclean, 2015, The Lancet. Respiratory medicine.

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.

R. Scheule, J. Davies, S. Hyde, 2013, Biomaterials.

Detection of CFTR transgene mRNA expression in respiratory epithelium isolated from the murine nasal cavity

D. Porteous, R. Scheule, Seng H. Cheng, 2010, The journal of gene medicine.

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

M. Hasegawa, S. Hyde, R. Farley, 2012, American journal of respiratory and critical care medicine.

CFTR gene transfer to human cystic fibrosis pancreatic duct cells using a Sendai virus vector.

A. Mehta, P. Hegyi, Z. Rakonczay, 2007, Journal of cellular physiology.

Safety and adverse events

A. Nicholson, D. Hansell, A. Maclean, 2016 .